RecruitingPhase 4NCT05936580
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Principal Investigator
- Johannes Oldenburg, Prof.Experimental Haematology and Transfusion Medicine, University Clinic Bonn
- Intervention
- Nuwiq(drug)
- Enrollment
- 28 target
- Eligibility
- 12 years · FEMALE
- Timeline
- 2026 – 2027
Study locations (15)
- UT Health San Antonio, San Antonio, Texas, United States
- Helsinki University Hospital,Coagulation Disorder Unit, Helsinki, Finland
- Avenue de la République, Chambray-lès-Tours, France
- CHU de Nantes Hôtel-Dieu, Nantes, France
- Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin, Bonn, Germany
- Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany
- Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik, Hamburg, Germany
- Aziendo Ospedaliera "Puglieze Ciaccio", Catanzaro, Italy
- Policlinico "P. Giaconne", Palermo, Italy
- Clinical Center for Serbia, Belgrade, Serbia
- Hospital Universitario la Paz, Madrid, Spain
- Hospital Universitario Virgen del Rocio, Seville, Spain
- Insel Spital Bern, Bern, Switzerland
- St. James's University Hospital, Leeds, United Kingdom
- Centro Hospitalario Pereira Rossell, Montevideo, Uruguay
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05936580 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota
- RECRUITINGNCT06352216Prevalence of Synovitis in Patients With Haemophilia AUniversity Hospital, Bonn